vs
Side-by-side financial comparison of Citi Trends Inc (CTRN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Citi Trends Inc is the larger business by last-quarter revenue ($197.1M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -3.5%, a 5.1% gap on every dollar of revenue. On growth, Citi Trends Inc posted the faster year-over-year revenue change (10.1% vs 5.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -4.3%).
Citi Trends, Inc. is an American retail clothing chain selling discounted products targeted primarily at African-American customers.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CTRN vs PCRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $197.1M | $177.4M |
| Net Profit | $-6.9M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | -3.7% | 3.9% |
| Net Margin | -3.5% | 1.6% |
| Revenue YoY | 10.1% | 5.0% |
| Net Profit YoY | 3.6% | — |
| EPS (diluted) | $-0.86 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $197.1M | $196.9M | ||
| Q3 25 | $190.8M | $179.5M | ||
| Q2 25 | $201.7M | $181.1M | ||
| Q1 25 | $211.2M | $168.9M | ||
| Q4 24 | $179.1M | $187.3M | ||
| Q3 24 | $176.6M | $168.6M | ||
| Q2 24 | $186.3M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-6.9M | — | ||
| Q3 25 | $3.8M | $5.4M | ||
| Q2 25 | $871.0K | $-4.8M | ||
| Q1 25 | $-14.2M | $4.8M | ||
| Q4 24 | $-7.2M | — | ||
| Q3 24 | $-18.4M | $-143.5M | ||
| Q2 24 | $-3.4M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -3.7% | 1.2% | ||
| Q3 25 | 1.8% | 3.5% | ||
| Q2 25 | 0.2% | 4.7% | ||
| Q1 25 | 0.6% | 1.2% | ||
| Q4 24 | -4.9% | 13.2% | ||
| Q3 24 | -14.1% | -82.8% | ||
| Q2 24 | -3.7% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -3.5% | — | ||
| Q3 25 | 2.0% | 3.0% | ||
| Q2 25 | 0.4% | -2.7% | ||
| Q1 25 | -6.7% | 2.8% | ||
| Q4 24 | -4.0% | — | ||
| Q3 24 | -10.4% | -85.1% | ||
| Q2 24 | -1.8% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.86 | $0.05 | ||
| Q3 25 | $0.46 | $0.12 | ||
| Q2 25 | $0.11 | $-0.11 | ||
| Q1 25 | $-1.70 | $0.10 | ||
| Q4 24 | $-0.86 | $0.38 | ||
| Q3 24 | $-2.21 | $-3.11 | ||
| Q2 24 | $-0.42 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $107.8M | $653.9M |
| Total Assets | $464.3M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $107.8M | $693.1M | ||
| Q3 25 | $113.2M | $727.2M | ||
| Q2 25 | $108.6M | $757.8M | ||
| Q1 25 | $113.2M | $798.5M | ||
| Q4 24 | $130.3M | $778.3M | ||
| Q3 24 | $136.6M | $749.6M | ||
| Q2 24 | $154.8M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $464.3M | $1.3B | ||
| Q3 25 | $457.4M | $1.3B | ||
| Q2 25 | $437.4M | $1.5B | ||
| Q1 25 | $462.8M | $1.6B | ||
| Q4 24 | $467.1M | $1.6B | ||
| Q3 24 | $506.7M | $1.5B | ||
| Q2 24 | $484.1M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.6M | — |
| Free Cash FlowOCF − Capex | $767.0K | — |
| FCF MarginFCF / Revenue | 0.4% | — |
| Capex IntensityCapex / Revenue | 4.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $11.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $8.6M | $43.7M | ||
| Q3 25 | $3.9M | $60.8M | ||
| Q2 25 | $-11.0M | $12.0M | ||
| Q1 25 | $28.5M | $35.5M | ||
| Q4 24 | $-18.4M | $33.1M | ||
| Q3 24 | $5.6M | $53.9M | ||
| Q2 24 | $-19.6M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $767.0K | $43.5M | ||
| Q3 25 | $-1.7M | $57.0M | ||
| Q2 25 | $-13.1M | $9.3M | ||
| Q1 25 | $26.0M | $26.9M | ||
| Q4 24 | $-20.4M | $31.0M | ||
| Q3 24 | $1.7M | $49.8M | ||
| Q2 24 | $-21.2M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 0.4% | 22.1% | ||
| Q3 25 | -0.9% | 31.7% | ||
| Q2 25 | -6.5% | 5.1% | ||
| Q1 25 | 12.3% | 15.9% | ||
| Q4 24 | -11.4% | 16.6% | ||
| Q3 24 | 0.9% | 29.6% | ||
| Q2 24 | -11.4% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.0% | 0.1% | ||
| Q3 25 | 2.9% | 2.2% | ||
| Q2 25 | 1.0% | 1.5% | ||
| Q1 25 | 1.2% | 5.1% | ||
| Q4 24 | 1.1% | 1.1% | ||
| Q3 24 | 2.2% | 2.4% | ||
| Q2 24 | 0.9% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.01× | 11.20× | ||
| Q2 25 | -12.59× | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTRN
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
